Eblasakimab is a Monoclonal Antibody owned by Aslan Pharmaceuticals, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.
ASLAN-004 is a fully human monoclonal antibody acting against interleukin-13 receptor alpha and IL4. The drug candidate block the binding and signal transduction of both IL4 and IL13. By targeting IL-13,it blocks type 2 receptor comlex. This results in the inhibition of JAK1, STAT3 and STAT6 pathway. The drug candidate results in the inhibition of bronchoconstriction and other asthma related allergic reactions and also causes inhibition of IL-13 signalling which acts as an immune checkpoint for tumour evasion and enhances the immune infiltrate in the tumour microenvironment.
The revenue for Eblasakimab is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eblasakimab NPV Report.
eblasakimab (ASLAN-004) is under development for the treatment of allergic disease such as asthma, unspecified type-2 driven disease and atopic eczema. It is administered through intravenous and subcutaneous route. The drug candidate is a monoclonal antibody act against interleukin-13 receptor alpha 1 and IL-4. It was under development for the treatment of solid tumors.
Aslan Pharmaceuticals Overview
Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore.
The operating loss of the company was US$31.5 million in FY2021, compared to an operating loss of US$16.4 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$16.2 million in FY2020.
Quick View – Eblasakimab
|Highest Development Stage|